Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts

Journal of Psychiatric Research

Volumn 78, Issue , 2016, Pages 86-93

  Suppes, Trisha ^a   Kroger, Hans ^b   Pikalov, Andrei ^b   Loebel, Antony ^b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Bipolar depression; Bipolar disorder; Lithium; Lurasidone; Major depressive episode; Valproate

Indexed keywords

LITHIUM; LURASIDONE; PLACEBO; VALPROIC ACID; ANTIDEPRESSANT AGENT; LITHIUM DERIVATIVE; TRANQUILIZER;

ADULT; AGED; AKATHISIA; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERSALIVATION; HYPERSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMOTOR RETARDATION; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCREENING; SOMNOLENCE; TREMOR; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; LEAST SQUARE ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; LEAST-SQUARES ANALYSIS; LITHIUM COMPOUNDS; LURASIDONE HYDROCHLORIDE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84962921387     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2016.03.012     Document Type: Article

References (35)

1. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
2. Bech P., Tanghøj P., Andersen H.F., Overø K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacol. Berl. 2002, 163:20-25.
3. Cerullo M.A., Strakowski S.M. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr. 2013, 18:199-208.
4. Endicott J., Nee J., Harrison W., et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol. Bull. 1993, 29:321-326.
5. Goldberg J.F., Brooks J.O., Kurita K., et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J. Clin. Psychiatry 2009, 70:155-162.
6. Goldstein B.I., Fagiolini A., Houck P., et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009, 11:657-662.
7. Greil W., Häberle A., Haueis P., et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the international AMSP project between 1994 and 2009. J. Affect Disord. 2012, 136:534-542.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Publication (ADM) 1976, National Institute of Mental Health, Rockville, MD, 76-338.
9. Haeberle A., Greil W., Russmann S., et al. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry 2012 Sep 21, 12:153.
10. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959, 32:50-55.
11. Hooshmand F., Miller S., Dore J., et al. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011. J. Affect Disord. 2014, 155:283-287.
12. Iovieno N., Papakostas G.I. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?. J. Clin. Psychiatry 2012, 73:676-683.
13. Ketter T.A., Miler S., Wang P.W., et al. Treatment of acute bipolar deprssion. Advances in Treatment of Bipolar Disorders 2015, American Psychiatric Publishing. T.A. Ketter (Ed.).
14. Licht R.W., Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology 2002, 161:143-151.
15. Loebel A., Cucchiaro J., Silva R., et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171:160-168.
16. Loebel A., Cucchiaro J., Silva R., et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry 2014, 171:169-177.
17. Meltzer H.Y., Cucchiaro J., Silva R., et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 2011, 168:957-966.
18. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 132:382-389.
19. Nakamura M., Ogasa M., Guarino J., et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo controlled trial. J. Clin. Psychiatry 2009, 70:829-836.
20. Nasrallah H.A., Cucchiaro J.B., Mao Y., et al. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015, 20:140-147.
21. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
22. Nivoli A.M., Colom F., Murru A., et al. New treatment guidelines for acute bipolar depression: a systematic review. J. Affect Disord. 2011, 129:14-26.
23. Ostacher M.J., Suppes T., Swann A.C., et al. Patterns of response to aripiprazole, lithium, haloperidol, and placebo across factor scores of mania. Int. J. Bipolar Disord. 2015, 3:11. 10.1186/s40345-015-0026-0.
24. Pacchiarotti I., Bond D.J., Baldessarini R.J., et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 2013, 170:1249-1262.
25. Posner K., Brown G.K., Stanley B., et al. The columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 2011, 168:1266-1277.
26. Rush A.J., Trivedi M.H., Ibrahim H.M., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 2003, 54:573-583.
27. Sachs G.S. Strategies for improving treatment of bipolar disorder: integration of measurement and management. Acta Psychiatr. Scand. Suppl. 2004, 7-17.
28. Sachs G.S., Ice K.S., Chappell P.B., et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011, 72:1413-1422.
29. Selle V., Schalkwijk S., Vázquez G.H., et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014, 47:43-52.
30. Sheehan D.V. The Anxiety Disease 1983, Bantam Books, New York.
31. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):22-33.
32. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
33. Thase M.E., Jonas A., Khan A., et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 2008, 28:13-20.
34. Vancampfort D., Vansteelandt K., Correll C.U., et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 2013, 170:265-274.
35. Young R.C., Biggs J.T., Ziegler V.E., et al. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133:429-435.